relapsed/refractory diffuse large B cell lymphoma

January 9, 2017

New CAR T-cell Therapy Shows ‘Remarkable’ Promise for Highly Refractory Lymphoma

News

Patients with refractory diffuse large B-cell lymphoma (DLBCL) could greatly benefit from a new CAR T-cell therapy called KTE-C19, according to recently published data from the Phase 1 ZUMA-1 trial. ... Read more

February 26, 2016February 26, 2016

Phase 2 Trial of R/R Diffuse Large B-cell Lymphoma Treatment Is Now Enrolling Patients

News

ProNAi Therapeutics, Inc, a clinical stage oncology company that develops therapeutic drugs based on its proprietary DNA interference (DNAi) technology platform, is currently enrolling patients in Wolverine, a clinical trial ... Read more

December 15, 2015December 15, 2015

Study in Advanced B Cell Lymphoma Patients Reports Good Results and an Expansion

News

Curis, Inc., recently presented promising results from the Phase 1 study of its drug candidate CUDC-907a in severely pre-treated patients with relapsed/refractory diffuse large B cell lymphoma (RR-DLBCL). The results, from the ongoing trial’s finished dose ... Read more